Virios therapeutics announces closing of initial public offering and full exercise of underwriter's over-allotment option

Atlanta--(business wire)--virios therapeutics, inc. (nasdaq: viri), a biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response, today announced the closing of its initial public offering of 3,450,000 shares of its common stock at a public offering price of $10.00 per share, which includes 450,000 shares sold upon full exercise of the underwriter's option to purchase additional common shares. the gross proce
VIRI Ratings Summary
VIRI Quant Ranking